Thrombotic microangiopathy (TMA) after kidney transplantation is an uncommon and challenging cause of graft dysfunction and is associated with early graft loss. An idiosyncratic endothelial reaction to calcineurin inhibitors (CNIs) has been implicated as a frequent cause of TMA. This reaction is marked by uncontrolled activation of complement and subsequent cellular destruction. Usual therapy consists of withdrawal of the inciting drug and plasmapheresis to minimize levels of circulating complement. Recently, eculizumab, a monoclonal antibody to complement component C5, has been used for the treatment of atypical hemolytic uremic syndrome. Belatacept, an inhibitor of T cell costimulatory protein CTLA-4 has been used in immunosuppression strategies aimed at minimization of CNI. Here we report the first case of treatment of CNI-associated TMA/hemolytic uremic syndrome with withdrawal of tacrolimus and initiation of both belatacept and eculizumab. The case describes a favorable clinical course for both graft and patient, and is accompanied by a review of the literature.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2016.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation.
Br J Clin Pharmacol
July 2024
Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
In solid organ transplantation (SOT), biologicals such as recombinant therapeutic proteins, monoclonal antibodies, fusion proteins and conjugates are increasingly used for immunosuppression, desensitization, ABO (blood group) incompatibility, antibody-mediated rejections and atypical haemolytic uremic syndrome. In this paper, we review the medical evidence available for biologicals used in SOT and the potential for improvement by the application of therapeutic drug monitoring (TDM) and model-informed precision dosing. Biologicals are used for off-label indications within the field of SOT, building on the experience from their use on labelled indications.
View Article and Find Full Text PDFSafety and Efficacy of Very Early Conversion to Belatacept in Pediatric Kidney Transplantation with Transplant-Associated Thrombotic Microangiopathy: Case Study and Review of Literature.
Clin Pract
May 2024
Division of Pediatric Nephrology, Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA.
The inhibition of co-stimulation during T-cell activation has been shown to provide effective immunosuppression in kidney transplantation (KT). Hence, the conversion from calcineurin inhibitor (CNI) to belatacept is emerging as a potential alternate maintenance immunosuppressive therapy in those with transplant-associated thrombotic microangiopathy (TA-TMA) or in the prevention of TA-TMA. We present a 17-year-old male who presented with biopsy-proven CNI-associated TA-TMA immediately post-KT.
View Article and Find Full Text PDFBeyond Immunosuppression: The Intricate Relationship Between Tacrolimus and Microangiopathy.
Cureus
November 2023
Internal Medicine, Penn State Health Hershey Medical Center, Hershey, USA.
Tacrolimus, widely known as Prograf, has become the preferred immunosuppressant for preventing graft rejection in solid organ transplant recipients, particularly in steroid-sparing regimens. Its efficacy and reduced risk of acute and chronic rejection compared to cyclosporine have made it the preferred treatment option for transplant patients. However, tacrolimus has drawbacks as it is associated with adverse effects, such as renal tubular necrosis, kidney failure, hypertension, metabolic acidosis, and new-onset diabetes mellitus.
View Article and Find Full Text PDFBiologic drugs in the treatment of juvenile dermatomyositis: a literature review.
Clin Rheumatol
February 2024
Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Article Synopsis
- There is ongoing debate in the medical community about which biologic therapies are most effective for treating juvenile dermatomyositis (JDM), and this review explores previous studies on the topic.
- The analysis of 74 articles revealed that rituximab (RTX) and tumor necrosis factor (TNF) inhibitors are the most frequently used biologic treatments, showing varying degrees of effectiveness depending on the patient's specific condition.
- Adverse events were reported in nearly half of the cases, indicating a need for more controlled studies to determine the best timing and usage of biologics in JDM treatment.
COVID-19 vaccination and Atypical hemolytic uremic syndrome.
Front Immunol
December 2022
Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, Netherlands.
Introduction: COVID-19 vaccination has been associated with rare but severe complications characterized by thrombosis and thrombocytopenia.
Methods And Results: Here we present three patients who developed or relapse atypical hemolytic uremic syndrome (aHUS) in native kidneys, a median of 3 days (range 2-15) after mRNA-based (Pfizer/BioNTech's, BNT162b2) or adenoviral (AstraZeneca, ChAdOx1 nCoV-19) COVID-19 vaccination. All three patients presented with evident hematological signs of TMA and AKI, and other aHUS triggering or explanatory events were absent.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!